IMBdx아이엠비디엑스

IMBdx remains deeply loss-making despite revenue growth, with its share price down about 75% over the past year.

IMBdx, a Korean liquid biopsy company focused on cancer diagnosis and monitoring, reported trailing twelve-month revenue of ₩5.6B against an operating loss of ₩8.6B as of H1 2026. It held ₩11.5B in cash and no reported borrowings, and its shares closed at ₩2,605 on 16 October 2026, well below the 52-week high of ₩12,990.

What stands out

• Revenue grew 56.4% in 2025 to ₩5.3B, but the operating margin was still about -163% that year.
• Trailing operating loss of ₩8.6B and free cash flow of -₩7.8B show heavy ongoing cash burn.
• Cash of ₩11.5B exceeds the trailing free cash outflow, and liabilities are low at 5.7% of equity.
• Price-to-book is 1.6 and price-to-sales is 6.7, but there is no meaningful earnings-based valuation since net income is negative.
• Foreign ownership fell from 6.3% to 5.7% over the past 60 days, and foreign investors were net sellers over the last 20 days.

What to watch

• The next quarterly and annual filings, to see whether losses narrow relative to the ₩11.5B cash position.
• Insider shareholding reports, which were filed frequently in June and July 2026.
• Dependence on purchased reagents, probes and sequencing flowcells, largely from foreign suppliers, which the profile names as a supply exposure; the data does not describe any specific supply issues or news.